

Synthesis of β -Haloketones by β -Addition Reactions of α,β -Unsaturated Ketones with BX_3 ($X = Br, Cl$) as Halide Source

Adam Shih-Yuan Lee,* Shu-Huei Wang and Yu-Ting Chang
Department of Chemistry, Tamkang University, New Taipei City, Taiwan 251

(Received: Aug. 1, 2013; Accepted: Sept. 25, 2013; Published Online: Dec. 9, 2013; DOI: 10.1002/jccs.201300394)


A series of β -bromoketones and β -chloroketones were synthesized by the addition reactions of α,β -unsaturated ketones under BX_3 ($X = Br, Cl$) and ethylene glycol reaction system. The α,β -unsaturated ester also was successfully converted to its corresponding β -bromoester under the reaction condition.

Keywords: β -Bromoketone; β -Chloroketone; α,β -Unsaturated ketone; β -Addition reaction; BBr_3 ; BCl_3 .

INTRODUCTION

A β -substituted carbonyl compound is potentially biological active molecule and the important synthetic intermediate in organic synthesis.^{1–4} Synthetic methodologies for synthesis of β -substituted carbonyl compounds are typically produced by the addition reactions such as Aldol-type reaction,^{5,6} organocopper addition reaction^{7,8} and Michael addition reaction.^{9,10} Conjugate addition of organometallic reagent to α,β -unsaturated carbonyl compound is the commonly used method for specific introduction of a substituent to the β -position of carbonyl functionality.¹¹ Recently, our laboratory reported the synthesis of β -methoxyketones, β -aminoketones **B**, and β -amidoketones by a Lewis acids promoted β -addition reactions of α,β -unsaturated ketones under mild reaction conditions.^{12,13} A contaminated β -chloroketone **C** was usually observed and characterized when Lewis acids such as $AlCl_3$ and $ZrCl_4$ were used for promotion of β -additional reaction of α,β -unsaturated ketone (Scheme 1). The formation of β -chloroketone as side product also was observed and reported by other addition reaction conditions.^{14,15} Some synthetic applications^{16–22} of β -halocarbonyl compounds such as β -bromoketone and β -bromoester have been reported in the literatures. To our knowledge, only a few direct preparation of β -chlorocarbonyl compounds which by reaction of α,β -unsaturated ketone with excess Me_3SiCl/H_2O reaction condition²³ and β -additional reaction of β -methylsulfonyl ester²⁴ with $AlCl_3$ have been reported in the literatures. The difficult preparations of β -halocarbonyl compounds restrict their further synthetic applications.^{23–26} Thus, we expected that the preparation of β -chloroketone may be achieved by the Michael addition reaction of α,β -unsaturated ketone

Scheme 1. Synthesis of β -*N*-tosylaminoketones




with Lewis acid $AlCl_3$ which serves as chloride source by introducing promotion agents.

RESULTS AND DISCUSSIONS

The first test of our approach was examined by reaction of 1-phenyl-pent-3-en-2-one **A** and Lewis acid $AlCl_3$ with 2 drops of ammonia solution as promoting reagent in CH_2Cl_2 and the reaction mixture was stirred at room temperature (Scheme 2). The reaction mixture was stirred at room temperature for 42 hours and the expected product β -chloroketone **C** (47%) was obtained with recovery of 1-phenyl-pent-3-en-2-one **A** (18%).

The higher yield of β -chloroketone **C** (84%) was achieved when promoter ethylene glycol (3 equivalents to $AlCl_3$) was used and much shorter reaction time also was observed. We think that BCl_3 may release chloride as nucleophile easier than $AlCl_3$ when ethylene glycol was introduced as promoter under the reaction condition. Therefore, a reaction mixture of 1-phenyl-pent-3-en-2-one **A** (1.0 equivalent), BCl_3 (1.0 equivalent) and ethylene glycol (1.0 equivalent) in CH_2Cl_2 was investigated and stirred at 0 °C. The experimental results showed that β -chloroketone **C** was afforded with 85% and the reaction time was shortened from 5 days to half an hour. The formation yield was dramatically improved to 96% when 1.2 equivalents of BCl_3

* Corresponding author. Tel: +8862-2621-5656#2543; Fax: +8862-2622-3830; E-mail: adamlee@mail.tku.edu.tw

Scheme 2. Optimization of preparation of β -chloroketone


• 1.0 $AlCl_3$, 2 drops NH_3 , r.t., 42 h	47% (C) + 18% (A)
• 1.0 $AlCl_3$, 1.0 $HOCH_2CH_2OH$, r.t., 5 days	55% (C) + 13% (A)
• 1.0 $AlCl_3$, 2.0 $HOCH_2CH_2OH$, r.t., 5 days	72% (C) + 11% (A)
• 1.0 $AlCl_3$, 3.0 $HOCH_2CH_2OH$, r.t., 42 h	84% (C)
• 1.0 BCl_3 , 1.0 $HOCH_2CH_2OH$, 0 °C, 0.5 h	85% (C)
• 1.2 BCl_3 , 1.2 $HOCH_2CH_2OH$, 0 °C, 0.5 h	96% (C)
• 1.2 BBr_3 , 1.2 $HOCH_2CH_2OH$, 0 °C, 0.5 h	96% (C)

and $HOCH_2CH_2OH$ to substrate were used as the reaction system. Thus, we further investigated this method for the preparation of β -bromoketone by reaction of BBr_3 as bromide source with 1-phenyl-pent-3-en-2-one under the reaction condition. As shown in Scheme 2, β -bromoketone was also obtained with high yield (96%) under the reaction condition. Herewith, we wish to report the synthesis of β -haloketones by the β -additional reactions of α,β -unsaturated ketones with BX_3 ($X = Br, Cl$)/ $HOCH_2CH_2OH$ reaction system.

To understand and expand the scope for synthesis of β -haloketones by this reaction system BX_3 ($X = Br, Cl$)/ $HOCH_2CH_2OH$, a series of α,β -unsaturated ketones was investigated and the results are shown in Table 1. The experimental results showed that alkyl and aryl α,β -unsaturated ketones were successfully converted to their corresponding β -bromoketones and β -chloroketones under the reaction condition.

A few previous reports showed that β -bromoester was used for synthesis of some synthetic intermediates and biologically active compounds.¹⁶⁻²¹ Therefore, we further investigated the reaction of α,β -unsaturated ester under this reaction condition. BBr_3 was added dropwise to a solution of methyl acrylate and ethylene glycol in CH_2Cl_2 at 0 °C and then the reaction mixture was stirred at room temperature for 24 hours. As shown in Scheme 3, a 96% yield of β -bromoester was obtained with longer reaction time which compared to α,β -unsaturated ketone under this reaction condition.

To understand and expand the synthetic applications of β -haloketones, we further investigated the reduction reaction of β -bromoketone by using AIBN/ Bu_3SnH reducing


Table 1. Synthesis of β -bromoketones and β -chloroketones

Entry	Substrate	Product	Yield (%)	
			X = Cl	X = Br
1	$CH_3CH_2CH_2CH_2COCH=CHCH_3$	$CH_3CH_2CH_2CH_2COCH_2CH(X)CH_3$	88%	89%
2			78%	71%
3			74%	70%
4			82%	85%
5			96%	96%
6			76%	79%
7			80%	84%

Scheme 3. Synthesis of β -bromoester


* 1.0 BBr_3 , 1.0 $HOCH_2CH_2OH$, CH_2Cl_2 , 0 °C-r.t., 24 h	87%
* 1.2 BBr_3 , 1.2 $HOCH_2CH_2OH$, CH_2Cl_2 , 0 °C-r.t., 24 h	96%

agents.²⁸ The β -bromoketone **C** was introduced into AIBN (azobis(isobutyronitrile)) and Bu_3SnH (tributyltin hydride) in benzene and the reaction mixture was refluxed for 11 hours (Scheme 4).

Scheme 4. Reduction reactions of β -bromoketones


X = Br	* 0.15 AIBN, 1.3 nBu_3SnH , PhH, reflux, 11 h	D (83%) + A (5%)
X = Cl	* 0.15 AIBN, 1.3 nBu_3SnH , PhH, reflux, 6 h	D (64%) + A (4%)

The experimental results showed that β -bromoketone undergo dehalogenation reaction and which was converted to its corresponding hydrogenated product **D** (83%) with small amount of contaminated α,β -unsaturated ketone **A** (5%). β -Chloroketone also underwent this dehalogenation

reaction and a lower yield of product **D** (64%) was obtained with small amount of 1-phenyl-pent-3-en-2-one **A** (4%). This reaction scheme may provide an alternative method for hydrogenation reaction of α,β -unsaturated ketone to hydrogenated ketone.

As a conclusion, we demonstrate here a simple and an efficient method for the synthesis of β -bromoketones, β -chloroketones and β -bromoesters under $\text{BX}_3/\text{HOCH}_2\text{CH}_2\text{OH}$ reaction conditions.

EXPERIMENTAL

General. All reagents were purchased from Aldrich and Riedel-deHaen and all were used directly without further purification. All experiments were carried out under a nitrogen atmosphere which was dried primarily by passing through a column of potassium hydroxide (KOH) layered with calcium sulfate (CaSO_4). Thin-layer chromatography (TLC) analysis was performed on a plastic plate (or aluminum sheet) precoated with silica gel (Merck, 5554 Silica gel 60F254). Column chromatography was performed using silica gel (Merck 230-400 mesh) and ethyl acetate/hexane mixture as the eluent. The ^1H NMR (proton nuclear magnetic resonance) spectra were recorded at 300 MHz (Bruker-AC300P) with deuteriochloroform (CDCl_3 , Aldrich 99.8 atom% D) as the solvent and the internal standard. The ^{13}C NMR (carbon nuclear magnetic resonance) spectra were recorded at 75.5 MHz (Bruker-AC300P) with CDCl_3 as the solvent and the internal standard. Mass spectra (MS) were recorded on JOEL SX-102A and VG 70-250S spectrophotometers and are reported in m/z units for the most abundant peaks. Infrared spectra (IR) were recorded on a Bruker Tensor 37 as a liquid film (neat).

A representative procedure for synthesis of β -bromoketone or β -chloroketone is as follows: BX_3 ($\text{X} = \text{Br}, \text{Cl}$) (1.2 mmol) was added dropwise to a solution of α,β -unsaturated ketone (1.0 mmol) and ethylene glycol (1.2 mmol) in CH_2Cl_2 (5 mL) at 0°C . The reaction mixture was stirred at 0°C for 30 minutes and distilled water (10 mL) was added slowly and then the reaction mixture was extracted with ether (10 mL \times 3). The combined organic layer was washed with brine (20 mL), dried with MgSO_4 , filtered, and the organic solvent was removed under reduced pressure.

2-Chlorooctan-4-one (Table 1, Entry 1). ^1H -NMR: δ 0.85 (3H, H_8 , t, $J = 7.3$), 1.20-1.30 (2H, H_7 , m), 1.46-1.56 (2H, H_6 , m), 1.48 (3H, H_1 , d, $J = 6.6$), 2.38 (2H, H_5 , t, $J = 7.4$), 2.66 (1H, H_3 , dd, $J = 16.8, 5.8$), 2.90 (1H, H_3 , dd, $J = 16.8, 7.7$), 4.40 (1H, H_2 , ddq, $J = 7.7, 7.4, 5.8$); ^{13}C -NMR: δ 13.7, 22.2, 25.1, 25.5, 43.2, 52.4, 207.3; IR: (neat) 2960 ($\text{sp}^3\text{-CH}$, w), 2933 ($\text{sp}^3\text{-CH}$, w), 1715 (C=O , m), 1377 (m), 1132 (m), 616 (C-Cl, m).

2-Bromooctan-4-one (Table 1, entry 1). ^1H -NMR: δ 0.85

(3H, H_8 , t, $J = 7.4$), 1.20-1.32 (2H, H_7 , m), 1.46-1.56 (2H, H_6 , m), 1.66 (3H, H_1 , d, $J = 6.6$), 2.37 (2H, H_5 , t, $J = 7.4$), 2.80 (1H, H_3 , dd, $J = 17.0, 6.0$), 3.04 (1H, H_3 , dd, $J = 17.0, 7.7$), 4.27 (1H, H_2 , ddq, $J = 7.7, 6.0, 6.0$); ^{13}C -NMR: δ 13.6, 22.1, 25.4, 26.1, 43.4, 53.0, 207.2; IR: (neat) 2961 ($\text{sp}^3\text{-CH}$, w), 2934 ($\text{sp}^3\text{-CH}$, w), 1716 (C=O , s), 1379 (m), 1132 (m).

3-Chloro-1-cyclopropylbutan-1-one (Table 1, entry 2).

^1H -NMR: δ 0.88-0.95 (2H, m), 1.05-1.10 (2H, m), 1.55 (3H, H_4 , d, $J = 6.6$), 1.88-1.96 (1H, m), 2.88 (1H, H_2 , dd, $J = 16.8, 7.3$), 3.10 (1H, H_2 , dd, $J = 16.8, 6.3$), 4.48 (1H, H_3 , ddq, $J = 7.3, 6.6, 6.3$); ^{13}C -NMR: δ 10.8, 20.9, 25.0, 52.2, 52.9, 206.9; IR: (neat) 2982 ($\text{sp}^3\text{-CH}$, w), 2931 ($\text{sp}^3\text{-CH}$, w), 1698 (C=O , m), 1388 (m), 1061 (m), 618 (C-Cl, m).

3-Bromo-1-cyclopropylbutan-1-one (Table 1, entry 2).

^1H -NMR: δ 1.65 (3H, H_4 , d, $J = 6.6$), 2.01-2.10 (2H, m), 2.54 (2H, d, $J = 7.0$), 2.82 (1H, H_2 , dd, $J = 17.0, 5.6$), 3.04 (1H, H_2 , dd, $J = 17.0, 8.1$), 3.37 (2H, t, $J = 6.6$), 4.42 (1H, H_3 , ddq, $J = 8.1, 5.6, 6.6$); ^{13}C -NMR: δ 25.9, 26.1, 32.9, 41.1, 42.8, 53.0, 205.5; IR: (neat) 2964 ($\text{sp}^3\text{-CH}$, w), 2922 ($\text{sp}^3\text{-CH}$, w), 1714 (C=O , s), 1375 (m), 1241 (m).

3-Chloro-1-phenylbutan-1-one (Table 1, entry 3). ^1H -

NMR: δ 1.62 (3H, H_4 , d, $J = 6.6$), 3.24 (1H, H_2 , dd, $J = 17.0, 6.6$), 3.57 (1H, H_2 , dd, $J = 17.0, 6.6$), 4.67 (1H, H_3 , ddq, $J = 6.6, 6.6, 6.6$), 7.44-7.49 (2H, m), 7.55-7.60 (1H, m), 7.93-7.96 (1H, m); ^{13}C -NMR: δ 25.2, 48.5, 52.6, 128.0, 128.6, 133.4, 136.6, 196.5; HRMS: m/z 182.0492 (calcd. for $\text{C}_{10}\text{H}_{11}\text{ClO}$, 182.0498); MS: m/z 186 (6, M+4), 184 (3, M+2), 182 (6, M), 165 (1), 147 (15), 130 (8), 115 (8), 106 (7), 105 (base), 91 (6), 77 (43); IR: (neat) 3061 ($\text{sp}^2\text{-CH}$, w), 2982 ($\text{sp}^3\text{-CH}$, w), 2929 ($\text{sp}^3\text{-CH}$, w), 1683 (C=O , s), 1448 (m), 1217 (m), 753 (s), 688 (s), 616 (C-Cl, m).

3-Bromo-1-phenylbutan-1-one (Table 1, entry 3). ^1H -

NMR: δ 1.81 (3H, H_4 , d, $J = 6.7$), 3.38 (1H, H_2 , dd, $J = 17.3, 6.7$), 3.71 (1H, H_2 , dd, $J = 17.3, 6.9$), 4.69 (1H, H_3 , ddq, $J = 6.9, 6.7, 6.7$), 7.44-7.49 (2H, m), 7.55-7.60 (1H, m), 7.93-7.96 (1H, m); ^{13}C -NMR: δ 26.4, 43.3, 49.3, 128.0, 128.6, 133.4, 136.4, 196.5; IR: (neat) 3061 ($\text{sp}^2\text{-CH}$, w), 2979 ($\text{sp}^3\text{-CH}$, w), 2922 ($\text{sp}^3\text{-CH}$, w), 1682 (C=O , m), 1448 (m), 1218 (m), 759 (m).

3-Chloro-1-(4-methoxyphenyl)butan-1-one (Table 1, entry 4). ^1H -NMR: δ 1.61 (3H, H_4 , d, $J = 6.6$), 3.18 (1H, H_2 , dd, $J = 16.8, 6.6$), 3.52 (1H, H_2 , dd, $J = 16.8, 6.7$), 3.86 (3H, OMe, s), 4.65 (1H, H_3 , ddq, $J = 6.7, 6.6, 6.6$), 6.94 (2H, d, $J = 9.0$), 7.93 (2H, d, $J = 9.0$); ^{13}C -NMR: δ 25.3, 48.2, 53.0, 55.5, 113.8, 130.0, 130.4, 163.8, 195.0; HRMS: m/z 212.0602 (calcd. for $\text{C}_{11}\text{H}_{13}\text{ClO}_2$, 212.0604); MS: m/z 215 (11, M+3), 214 (20, M+2), 213 (31, M+1), 212 (57, M), 177 (75), 134 (49), 135 (base), 107 (28); IR: (neat) 2973 ($\text{sp}^3\text{-CH}$, w), 2934 ($\text{sp}^3\text{-CH}$, w), 1674 (C=O , s), 1597 (s), 1167 (s), 1023 (m), 830 (s), 596 (C-Cl, m).

3-Bromo-1-(4-methoxyphenyl)butan-1-one (Table 1, entry 4). $^1\text{H-NMR}$: δ 1.78 (3H, H_4 , d, $J = 6.7$), 3.30 (1H, H_2 , dd, $J = 17.0, 6.8$), 3.64 (1H, H_2 , dd, $J = 17.0, 7.0$), 3.84 (3H, OMe, s), 4.68 (1H, H_3 , ddq, $J = 7.0, 6.8, 6.7$), 6.91 (2H, d, $J = 8.9$), 7.91 (2H, d, $J = 8.9$); $^{13}\text{C-NMR}$: δ 26.4, 43.8, 48.9, 55.4, 113.8, 129.5, 130.3, 163.7, 195.0; HRMS: m/z 256.0114 (calcd. for $C_{11}H_{13}BrO_2$, 256.0099); MS: m/z 259 (10, M+3), 258 (9, M+2), 257 (10, M+1), 256 (8, M), 177 (38), 176 (26), 136 (8), 135 (base); IR: (neat) 3006 (sp^2 -CH, w), 2988 (sp^3 -CH, w), 2923 (sp^3 -CH, w), 1673 (C=O, m), 1597 (m), 1260 (m), 1166 (m), 764 (s).

4-Chloro-1-phenyl-pentan-2-one (Table 1, entry 5). $^1\text{H-NMR}$: δ 1.48 (3H, H_5 , d, $J = 6.5$), 2.74 (1H, H_3 , dd, $J = 17.0, 6.0$), 3.00 (1H, H_3 , dd, $J = 17.0, 7.6$), 3.72 (2H, H_1 , s), 4.45 (1H, H_4 , ddq, $J = 7.6, 6.6, 6.0$), 7.19-7.38(5H, m); $^{13}\text{C-NMR}$: δ 25.0, 50.7, 51.5, 52.3, 127.2, 128.7, 129.4, 133.4, 204.5; MS: m/z 198 (4, M+2), 196 (12, M), 160 (8), 106 (21), 105 (71), 92 (18), 91 (base), 79 (10), 77 (52), 69 (64), 65 (28), 63 (10), 51 (6); IR: (neat) 3031 (sp^2 -CH, w), 2982 (sp^3 -CH, w), 1715 (C=O, s), 1127 (m), 699 (C-Cl, m).

4-Bromo-1-phenylpentan-2-one (Table 1, entry 5). $^1\text{H-NMR}$: δ 1.67 (3H, H_5 , d, $J = 6.6$), 2.88 (1H, H_3 , dd, $J = 17.2, 6.2$), 3.13 (1H, H_3 , dd, $J = 17.2, 7.6$), 3.71 (2H, H_1 , s), 4.49 (1H, H_4 , ddq, $J = 7.6, 6.6, 6.2$), 7.20-7.38(5H, m); $^{13}\text{C-NMR}$: δ 26.0, 42.9, 50.4, 52.1, 127.1, 128.7, 129.4, 133.3, 204.4; HRMS: m/z 240.0149 (calcd. for $C_{11}H_{13}BrO$, 240.0150); MS: m/z 243 (9, M+3), 242 (4, M+2), 241 (9, M+1), 240 (4, M), 161 (13), 149 (13), 123 (22), 121 (25), 92 (20), 91 (base), 90 (20), 89 (0), 65 (55); IR: (neat) 3060 (sp^2 -CH, w), 3029 (sp^2 -CH, w), 2960 (sp^3 -CH, w), 2927 (sp^3 -CH, w), 1714 (C=O, m), 1668 (m), 1285 (m), 778 (s).

4-Chloro-1-(naphthalen-5-yl)pentan-2-one (Table 1, entry 6). $^1\text{H-NMR}$: δ 1.43 (3H, H_5 , d, $J = 6.6$), 2.67 (1H, H_3 , dd, $J = 17.1, 5.7$), 2.98 (1H, H_3 , dd, $J = 17.1, 7.6$), 4.16 (2H, H_1 , dd, $J = 22.1, 15.9$), 4.45 (1H, H_4 , ddq, $J = 7.6, 6.6, 5.7$), 7.38~7.56 (4H, m), 7.81~7.90 (3H, m); $^{13}\text{C-NMR}$: δ 25.0, 49.1, 51.1, 52.4, 123.7, 125.6, 126.0, 126.6, 128.3, 128.4, 128.8, 130.2, 132.2, 134.0, 205.1; HRMS: m/z 246.0816 (calcd. for $C_{15}H_{15}ClO$, 246.0811); MS: m/z 249 (2, M+3), 248 (6, M+2), 247 (6, M+1), 246 (18, M), 210 (1), 144 (18), 141 (base), 139 (9), 115 (22); IR: (neat) 3047 (sp^2 -CH, w), 2981 (sp^3 -CH, w), 1714 (C=O, s), 1126 (m), 774 (C-Cl, s).

4-Bromo-1-(naphthalen-5-yl)pentan-2-one (Table 1, entry 6). $^1\text{H-NMR}$: δ 1.62 (3H, H_5 , d, $J = 6.6$), 2.82 (1H, H_3 , dd, $J = 17.3, 5.9$), 3.13 (1H, H_3 , dd, $J = 17.3, 7.7$), 4.15 (2H, H_1 , dd, $J = 22.4, 15.9$), 4.49 (1H, H_4 , ddq, $J = 7.7, 6.6, 5.9$), 7.39-7.57 (4H, m), 7.82-7.90 (3H, m); $^{13}\text{C-NMR}$: δ 26.1, 43.0, 48.8, 51.8, 123.7, 125.5, 125.9, 126.6, 128.2, 128.4, 128.8, 130.1, 132.1, 133.9,

205.0; HRMS: m/z 290.0312 (calcd. for $C_{15}H_{15}BrO$, 290.0306); MS: m/z 293 (2, M+3), 292 (8, M+2), 291 (2, M+1), 290 (8, M), 210 (15), 142 (17), 141 (base), 139 (17), 115 (32), 69 (48); IR: (neat) 3045 (sp^2 -CH, w), 2987 (sp^3 -CH, w), 2902 (sp^3 -CH, w), 1714 (C=O, m), 1126 (m), 775 (s).

4-Chloro-1-(thiophen-3-yl)pentan-2-one (Table 1, entry 7). $^1\text{H-NMR}$: δ 1.50 (3H, H_5 , d, $J = 6.6$), 2.74 (1H, H_3 , dd, $J = 17.0, 5.7$), 2.99 (1H, H_3 , dd, $J = 17.0, 7.6$), 3.74 (2H, H_1 , s), 4.44 (1H, H_4 , ddq, $J = 7.6, 6.6, 5.7$), 6.95 (1H, dd, $J = 4.9, 1.3$), 7.11 (1H, dd, $J = 2.9, 1.3$), 7.31 (1H, dd, $J = 4.9, 2.9$); $^{13}\text{C-NMR}$: δ 25.0, 44.9, 51.4, 52.3, 123.2, 126.1, 128.4, 133.0, 204.0; HRMS: m/z 203.0816 (calcd. for $C_{15}H_{15}ClO$, 203.0811); MS: m/z 205 (M+2, 4), 204 (M+1, 8), 203 (M, 56), 191 (10), 167 (20), 161 (4), 138 (16), 128 (6), 111 (52), 107 (32), 105 (base); IR: (neat) 3104 (sp^2 -CH, w), 2980 (sp^3 -CH, w), 1715 (C=O, s), 1126 (m), 776 (C-Cl, m).

4-Bromo-1-(thiophen-3-yl)pentan-2-one (Table 1, entry 7). $^1\text{H-NMR}$: δ 1.68 (3H, H_5 , d, $J = 6.8$), 2.88 (1H, H_3 , dd, $J = 17.2, 6.0$), 3.13 (1H, H_3 , dd, $J = 17.2, 7.6$), 3.73 (2H, H_1 , s), 4.35 (1H, H_4 , ddq, $J = 7.6, 6.8, 6.0$), 6.95 (1H, dd, $J = 4.9, 1.0$), 7.10 (1H, dd, $J = 2.9, 1.0$), 7.30 (1H, dd, $J = 4.9, 2.9$); $^{13}\text{C-NMR}$: δ 26.0, 42.9, 44.7, 52.1, 123.1, 126.0, 128.4, 132.9, 204.0; HRMS: m/z 245.9430 (calcd. for $C_9H_{11}BrOS$, 245.9714); MS: m/z 248 (15, M+2), 247 (3, M+1), 246 (25, M), 245 (12), 166 (12), 151 (34), 147 (42), 131 (36), 97 (42), 69 (13), 43 (56), 28 (base); IR: (neat) 3051 (sp^2 -CH, w), 2962 (sp^3 -CH, w), 2928 (sp^3 -CH, w), 1713 (C=O, m), 1264 (m), 731 (s), 702 (s).

ACKNOWLEDGMENTS

We thank the National Science Council of Taiwan (NSC 98-2119-M-032-002-MY3) and Tamkang University for financial support.

REFERENCES

- Mann, J. *Nature (London)* **1994**, *367*, 594.
- Panek, J. S.; Jain, N. F. *J. Org. Chem.* **2001**, *66*, 2747.
- Schreiber, S. L. *Science* **1991**, *251*, 283.
- Corey, E. J.; Trybulski, E. J.; Melvin, L. S., Jr.; Nicolaou, K. C.; Secrist, J. A.; Lett, R.; Scheldarke, P. W.; Falck, J. R.; Brunelle, D. J.; Haslanger, M. F.; Kim, S.; Yoo, S. *J. Am. Chem. Soc.* **1978**, *100*, 4618.
- Mukaiyama, T.; Narasaka, K. *Org. Synth.* **1987**, *65*, 6.
- Evans, D. A. In *Asymmetric Synthesis*; Morrison, J. D. Ed.; Academic Press Inc.: New York, 1984; Vol. 3, pp 1-274.
- Rositer, B. E.; Swingle, N. M. *Chem. Rev.* **1992**, *92*, 771.
- Krause, N.; Gerold, A. *Angew. Chem. Int. Ed. Engl.* **1997**, *36*, 186.
- Oare, D. A.; Heathcock, C. H. *Top. Stereochem.* **1989**, *19*, 227-407; **1991**, *20*, 87-170.

10. Yoshikoshi, A.; Miyashita, M. *Acc. Chem. Res.* **1985**, *18*, 284.
11. Larock, R. C. *Comprehensive Organic Transformations-A Guide to Functional Group Preparations*, 2nd ed.; John Wiley & Sons Inc.: New York, 1999; Chapter 15, pp 1567-1616.
12. Lee, A. S.-Y.; Wang, S.-H.; Chang, Y.-T.; Chu, S.-F. *Synlett* **2003**, 2359.
13. Lee, A. S.-Y.; Lin, M. C.; Lin, C. C.; Chang, Y.-T. *J. Chin. Chem. Soc.* **2010**, *57*, 795.
14. Roscales, S.; Rincon, A.; Buxaderas, E.; Csaky, A. G. *Tetrahedron Lett.* **2012**, *53*, 4721.
15. Bach, R. D.; Domagala, J. M. *J. Org. Chem.* **1984**, *49*, 4181.
16. Itoh, Y.; Kitaguchi, R.; Ishikawa, M.; Naito, M.; Hashimoto, Y. *Bioorg. Med. Chem.* **2011**, *19*, 6768.
17. Napolitano, C.; Natoni, A.; Santocanale, C.; Evensen, L.; Lorens, J. B.; Murphy, P. V. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 1167.
18. Napolitano, C.; McArdle, P.; Murphy, P. V. *J. Org. Chem.* **2010**, *75*, 7404.
19. Couladouros, E. A.; Mihou, A. P.; Bouzas, E. A. *Org. Lett.* **2004**, *6*, 977.
20. Ghosh, A. K.; Lee, H. Y.; Thompson, W. J.; Culberson, C.; Holloway, M. K.; McKee, S. P.; Munson, P. M.; Duong, T. T.; Smith, A. M.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Huff, J. R.; Anderson, P. S. *J. Med. Chem.* **1994**, *37*, 1177.
21. Carroll, F. I.; Berrang, B. D.; Linn, C. P. *J. Med. Chem.* **1980**, *23*, 581.
22. Rieke, R. D.; Hanson, M. V.; Brown, J. D. *J. Org. Chem.* **1996**, *61*, 2726.
23. Boudjouk, P.; Kim, B.-K.; Han, B.-H. *Synth. Commun.* **1996**, *26*, 3479.
24. Azzena, U.; Delogu, G.; Melloni, G.; Piccolo, O. *Tetrahedron Lett.* **1989**, *30*, 4555.
25. Ma, S.; Li, L.; Xie, H. *J. Org. Chem.* **1999**, *64*, 5325; Ma, S.; Li, L.; Xie, H. *J. Org. Chem.* **1999**, *64*, 5325.
26. Le Roux, C.; Gaspard-Iloughmane, H.; Dubac, J. *J. Org. Chem.* **1994**, *59*, 2238.
27. Li, H.; Zhang, F.-M.; Tu, Y.-Q.; Zhang, Q.-W.; Chen, Z.-M.; Chen, Z.-H.; Li, J. *Chem. Sci.* **2011**, *2*, 1839.
28. Jonasson, C.; Ronn, M.; Backvall, J.-E. *J. Org. Chem.* **2000**, *65*, 2122.